Prostate-specific antigen (PSA) levels in men 60 to 70 years of age predict aggressive prostate cancer in the PLCO cancer screening trial: Implications for risk-stratified screening Alexandra Berger
1:10 PM - 1:20 PM
Germline Genetic Associations with High-risk Prostate Cancer and Age at Diagnosis Brian T. Helfand, MD
1:20 PM - 1:30 PM
Psychological morbidity associated with a new diagnosis of prostate cancer: rates and predictors of depressive symptoms in the RADICAL PC study Gagan Fervaha, BSc, PhD, MD(c)
1:30 PM - 1:40 PM
Variation and Correlation of Facility-level Probabilities of Treatment in Men with Low-risk Prostate Cancer and Men with Limited Life Expectancy Marieke Johanna Krimphove
1:40 PM - 1:50 PM
Predicting Definitive Treatment in an Active Surveillance cohort using Group-based Trajectory Modeling Samuel Washington
1:50 PM - 2:00 PM
Comparison of external beam radiation therapy and robotic prostatectomy on patient reported outcomes after 5 years in men with unfavorable intermediate-risk and high-risk prostate cancer Aaron Laviana
2:00 PM - 2:10 PM
PATIENT REPORTED FUNCTIONAL OUTCOMES AFTER 5 YEARS IN MEN WITH LOW- AND FAVORABLE INTERMEDIATE-RISK PROSTATE CANCER Daniel D. Joyce
2:10 PM - 2:20 PM
Trends and Predictors of Adjuvant Therapy Following Radical Prostatectomy: An Analysis from the CaPSURE Registry Ashwin Balakrishnan
2:20 PM - 2:30 PM
Randomized Controlled Trial of a 6-month low carbohydrate intervention on weight and disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) Pao-Hwa Lin, PHD – Duke University Medical Center
2:30 PM - 2:40 PM
Definitive and Sustained Increase in Prostate Cancer Metastases in the United States Neal Patel, MD
2:40 PM - 2:50 PM
Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: A nationwide population-based study using the National Health Insurance Service database Jae Young Park, MD
2:50 PM - 3:00 PM
Risk of dementia following Androgen Deprivation Therapy for treatment of prostate cancer Karl Heinrich Tully
